Product Name:
COX1 (PTGS1)
Product Number:
ab-nn381-1
Target Full Name: Prostaglandin G/H synthase 1
Target Alias: EC:1.14.99.1; PGHS1; PGHS-1; Prostaglandin H2 synthase 1; Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase); PHS 1; EC 1.14.99.1; Prostaglandin-endoperoxide synthase 1; COX 3; PTGS1; PGH1_HUMAN; COX-1; PGG/HS; PTGHS; Cox3; PGH synthase 1; Cyclooxygenase-1; PHS1; Cyclooxygenase 1; Cyclooxygenase 3; included; Partial COX1 proteins; included; COX 1; COX1; PCOX1
Product Type Specific: COX1 pan-specific antibody
Antibody Code: NN381-1
Antibody Target Type: Pan-specific
Protein UniProt: P23219
Protein SigNET: COX1 (PTGS1)
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Synthetic peptide of human Cyclooxygenase
Production Method: Peptide Affinity purified
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline, 50% glycerol, 0.09% sodium azide
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting
Antibody Dilution Recommended: WB (1:1000); optimal dilutions for assays should be determined by the user.
Antibody Potency: Detects a medium ~70 kDa protein band in mouse kidney, rat brain and HeLa cell lysates by Western blotting.
Antibody Species Reactivity: This antibody detects the target protein in the following species due to conservation of amino acid sequence: Human | Rat | Mouse.
Antibody Positive Control: A 1:1000 dilution of SPC-707 was sufficient for detection of Cyclooxygenase in 15 µg of Human HeLa cell lysates by ECL immunoblot analysis using goat anti-rabbit IgG:HRP as the secondary antibody.
Antibody Specificity: High
Antibody Cross Reactivity: No other prominent cross-reactive proteins in mouse and rat brain, and HeLa cell lysates, except for a ~22 kDa protein in mouse brain and a ~90KDa protein in HeLa cells.
Related Product 1: COX2 Y446 phosphorylation antibody (Cat. No.: AB-PN695)
Related Product 2: COX4 (COX4I1) expression antibody (Cat. No.: AB-NN379-1)
Scientific Background: COX1 (Prostaglandin G/H synthase 1; PTGS1) is a constitutely produced cytoplasmic enzyme in the prostaglandin G/H synthase family, which converts arachidonate to prostaglandin H2 (PGH2). It is a dual cyclooxygenase and peroxidase that plays an important role in the biosynthesis pathway of prostanoids, a class of C20 oxylipins mainly derived from arachidonate ((5Z,8Z,11Z,14Z)-eicosatetraenoate, AA, C20:4(n-6)), with a particular role in the inflammatory response. The cyclooxygenase activity oxygenates AA to the hydroperoxy endoperoxide prostaglandin G2 (PGG2), and the peroxidase activity reduces PGG2 to the hydroxy endoperoxide prostaglandin H2 (PGH2), the precursor of all 2-series prostaglandins and thromboxanes. This is a committed step in prostanoid synthesis, particularly in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the generation of thromboxane A2 (TXA2), which promotes platelet activation and aggregation, vasoconstriction and proliferation of vascular smooth muscle cells. It can also use linoleate (LA, (9Z,12Z)-octadecadienoate, C18:2(n-6)) as substrate and produce hydroxyoctadecadienoates (HODEs) in a regio- and stereospecific manner, being (9R)-HODE ((9R)-hydroxy-(10E,12Z)-octadecadienoate) and (13S)-HODE ((13S)-hydroxy-(9Z,11E)-octadecadienoate) its major products. PTGS1 and PTGS2 are the targets of nonsteroidal anti-inflammatory drugs (NSAIDs) including aspirin and ibuprofen. Aspirin produces an irreversible inactivation of the enzyme through a serine acetylation. Inhibition of the PGHSs with NSAIDs acutely reduces inflammation, pain, and fever, and long-term use of these drugs reduces the risk of fatal thrombotic events, as well as the development of colon cancer and Alzheimer's disease. This description may include information annotated by UniProt and/or Google AI.